Company Contact: John F. DeBernardis, Ph.D., President & COO
(847) 573-8025 ext. 264
Agency Contact: Ira Weingarten/Steve Chizzik
Media Contact: Deanne Eagle
APPLIED NEUROSOLUTIONS' (OTC BB: APNS) BIOMARKER IMPROVES ON EARLY DIAGNOSIS OF ALZHEIMERS DISEASE
Philadelphia, PA, July 20, 2004--Results of a longitudinal study of patients with mild cognitive impairment (MCI) presented yesterday at the 9th International Conference on Alzheimer's Disease and Related Disorders, by Dr. Mony de Leon, Professor of Psychiatry at the New York University School of Medicine, indicated that biological markers could be combined with MRI (magnetic resonance imaging) to improve the diagnostic accuracy for MCI relative to normal controls, compared to diagnostic accuracy using MRI or memory tests alone.
While brain imaging is helpful in diagnosing Alzheimer's disease (AD), this approach alone produces results that are not diagnostically or pathologically specific. This study combined brain imaging with a biochemical test based upon a highly sensitive and specific biomarker. The results suggest the possibility of a new strategy for early detection of AD that can produce accurate early diagnoses of AD, commented Dr. de Leon.
The study utilized the biomarker p-tau 231 (tau protein that has been phosphorylated at amino acid 231), along with other biological markers and MRI images of the brain, to identify MCI patients, believed to be an early state prior to patients reaching the level of impairment consistent with Alzheimers disease, compared against a control group. It is believed that phosphorylated tau precedes the formation of neurofibrillary tangles, one of the two hallmark pathologies of AD that are associated with the damage to the memory systems of the brain. The paper by Dr. de Leon demonstrated the first longitudinal evidence between elevations in the p-tau 231 biomarker and the progressive hippocampal damage as determined by MRI. An Alzheimers diagnostic based on p-tau 231 is being developed by Applied NeuroSolutions, Inc., and has been shown to be an early and specific biomarker for AD patients.
Published work shows that our biomarker is able to distinguish a patient with Alzheimers disease from a patient who suffers from a different condition with similar symptoms, working hand-in-hand with imaging modalities to provide biochemical support to the imaging results, commented Dr. Daniel Kerkman, APNS Vice-President of R&D and part of the research team.
In partnership with a scientific team based at Albert Einstein College of Medicine, Applied NeuroSolutions is developing products to diagnose and treat Alzheimer's disease based on a novel theory of AD and its pathology. Key projects include a cerebrospinal fluid (CSF) test that can detect Alzheimers disease at an early stage with 85%-95% accuracy. The company is also developing a serum-based screening test to detect AD, as well as a new class of therapeutics to treat AD.
This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.